Advertisement

Vasopressin Antagonists in the Treatment of Water-Retaining Disorders

  • Sumit Kumar
    Affiliations
    Department of Nephrology, Presbyterian Hospital, Dallas, TX.
    Search for articles by this author
  • Tomas Berl
    Correspondence
    Address reprint requests to Tomas Berl, MD, Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado at Denver and Health Sciences Center, 4200 E. Ninth Ave, Box C281, Denver, CO 80262.
    Affiliations
    Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado at Denver and Health Sciences Center, Denver, CO.
    Search for articles by this author

      Summary

      The tools available to physicians for the treatment of hyponatremia, the most common of electrolyte disorders, are limited by lack of effectiveness, compliance difficulties, and toxicity problems. For this reason the development of novel oral antagonists of vasopressin provide a new approach to the management of these disorders. Since vasopressin plays a central role in the pathogenesis of most hyponatremic disorders, the inhibition of binding of the hormone to its receptors is likely to provide a most reliable and reproducible response leading to increases in free water excretion. This article reviews many of the studies that have been undertaken with this new class of agents, both in hypovolemic and hypervolemic settings.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Adrogue H.J.
        • Madias N.E.
        Hyponatremia.
        N Engl J Med. 2000; 342: 1581-1589
        • Anderson R.J.
        • Chung H.M.
        • Kluge R.
        • Schrier R.W.
        Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin.
        Ann Intern Med. 1985; 102: 164-168
        • Hoorn E.J.
        • Lindemans J.
        • Zietse R.
        Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management.
        Nephrol Dial Transplant. 2006; 21: 70-76
        • Hawkins R.C.
        Age and gender as risk factors for hyponatremia and hypernatremia.
        Clin Chim Acta. 2003; 337: 169-172
        • Ellison D.H.
        • Berl T.
        Clinical practice.
        N Engl J Med. 2007; 356: 2064-2072
        • Knepper M.A.
        Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin.
        Am J Physiol. 1997; 272: F3-F12
        • Chen S.
        • Jalandhara N.
        • Batlle D.
        Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists.
        Nat Clin Pract. 2007; 3: 82-95
        • Berl T.
        • Schrier R.W.
        Disorders of water balance.
        in: Schrier R.W. Renal and Electrolyte Disorders. 6th ed. Lippincott Williams & Wilkins, Philadelphia2003: 1-63
        • Thurman J.
        • Halterman R.
        • Berl T.
        Therapy of dysnatremic disorders.
        2nd ed. WB Saunders, Philadelphia2003
        • Mohmand H.K.
        • Issa D.
        • Ahmad Z.
        • Cappuccio J.D.
        • Kouides R.W.
        • Sterns R.H.
        Hypertonic saline for hyponatremia: risk of inadvertent overcorrection.
        Clin J Am Soc Nephrol. 2007; 2: 1110-1117
        • Macion-Dazard R.
        • Callahan N.
        • Xu Z.
        • Wu N.
        • Thibonnier M.
        • Shoham M.
        Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor.
        J Pharmacol Exp Ther. 2006; 316: 564-571
        • Serradeil-Le Gal C.
        • Lacour C.
        • Valette G.
        • Garcia G.
        • Foulon L.
        • Galindo G.
        • et al.
        Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
        J Clin Invest. 1996; 98: 2729-2738
        • Saito T.
        • Ishikawa S.
        • Abe K.
        • Kamoi K.
        • Yamada K.
        • Shimizu K.
        • et al.
        Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
        J Clin Endocrinol Metab. 1997; 82: 1054-1057
        • Decaux G.
        Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide.
        Am J Med. 2001; 110: 582-584
        • Wong F.
        • Blei A.T.
        • Blendis L.M.
        • Thuluvath P.J.
        A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
        Hepatology. 2003; 37: 182-191
        • Soupart A.
        • Gross P.
        • Legros J.J.
        • Alfoldi S.
        • Annane D.
        • Heshmati H.M.
        • et al.
        Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
        Clin J Am Soc Nephrol. 2006; 1: 1154-1160
        • Schrier R.W.
        • Gross P.
        • Gheorghiade M.
        • Berl T.
        • Verbalis J.G.
        • Czerwiec F.S.
        • et al.
        Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
        N Engl J Med. 2006; 355: 2099-2112
        • Ghali J.K.
        • Koren M.J.
        • Taylor J.R.
        • Brooks-Asplund E.
        • Fan K.
        • Long W.A.
        • et al.
        Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
        J Clin Endocrinol Metab. 2006; 91: 2145-2152
        • Zeltser D.
        • Rosansky S.
        • van Rensburg H.
        • Verbalis J.G.
        • Smith N.
        Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
        Am J Nephrol. 2007; 27: 447-457
        • Walter K.A.
        Conivaptan: new treatment for hyponatremia.
        Am J Health Syst Pharm. 2007; 64: 1385-1395
        • Kumar S.
        • Berl T.
        Sodium.
        Lancet. 1998; 352: 220-228
        • Schrier R.W.
        Decreased effective blood volume in edematous disorders: what does this mean?.
        J Am Soc Nephrol. 2007; 18: 2028-2031
        • Decaux G.
        Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
        J Lab Clin Med. 2001; 138: 18-21
        • Gerbes A.L.
        • Gulberg V.
        • Gines P.
        • Decaux G.
        • Gross P.
        • Gandjini H.
        • et al.
        Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.
        Gastroenterology. 2003; 124: 933-939
        • Schrier R.W.
        • Abraham W.T.
        Hormones and hemodynamics in heart failure.
        N Engl J Med. 1999; 341: 577-585
        • Gheorghiade M.
        • Abraham W.T.
        • Albert N.M.
        • Gattis Stough W.
        • Greenberg B.H.
        • O'Connor C.M.
        • et al.
        Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.
        Eur Heart J. 2007; 28: 980-988
        • Yancy C.W.
        Climbing the mountain of acute decompensated heart failure: the EVEREST Trials.
        JAMA. 2007; 297: 1374-1376
        • Gheorghiade M.
        • Niazi I.
        • Ouyang J.
        • Czerwiec F.
        • Kambayashi J.
        • Zampino M.
        • et al.
        Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
        Circulation. 2003; 107: 2690-2696
        • Gheorghiade M.
        • Gattis W.A.
        • O'Connor C.M.
        • Adams Jr, K.F.
        • Elkayam U.
        • Barbagelata A.
        • et al.
        Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
        JAMA. 2004; 291: 1963-1971
        • Konstam M.A.
        • Gheorghiade M.
        • Burnett Jr, J.C.
        • Grinfeld L.
        • Maggioni A.P.
        • Swedberg K.
        • et al.
        Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
        JAMA. 2007; 297: 1319-1331
        • Gheorghiade M.
        • Konstam M.A.
        • Burnett Jr, J.C.
        • Grinfeld L.
        • Maggioni A.P.
        • Swedberg K.
        • et al.
        Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
        JAMA. 2007; 297: 1332-1343
        • Abraham W.T.
        • Shamshirsaz A.A.
        • McFann K.
        • Oren R.M.
        • Schrier R.W.
        Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
        J Am Coll Cardiol. 2006; 47: 1615-1621
        • Udelson J.E.
        • Smith W.B.
        • Hendrix G.H.
        • Painchaud C.A.
        • Ghazzi M.
        • Thomas I.
        • et al.
        Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.
        Circulation. 2001; 104: 2417-2423
        • Udelson J.E.
        • McGrew F.A.
        • Flores E.
        • Ibrahim H.
        • Katz S.
        • Koshkarian G.
        • et al.
        Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
        J Am Coll Cardiol. 2007; 49: 2151-2159
        • Verbalis J.G.
        Vaptans for the treatment of hyponatremia: how, who, when and why.
        Nephrol Self Assessment Programs. 2007; 6: 199-209
        • Furst H.
        • Hallows K.R.
        • Post J.
        • Chen S.
        • Kotzker W.
        • Goldfarb S.
        • et al.
        The urine/plasma electrolyte ratio: a predictive guide to water restriction.
        Am J Med Sci. 2000; 319: 240-244
        • Kumar S.
        • Berl T.
        Diseases of water metabolism.
        in: Schrier R.W. Berl T. Atlas of diseases of the kidney. Blackwell Science: Philadelphia, 1999: 1-22
        • Lee C.R.
        • Watkins M.L.
        • Patterson J.H.
        • Gattis W.
        • O'Connor C.M.
        • Gheorghiade M.
        • et al.
        Vasopressin: a new target for the treatment of heart failure.
        Am Heart J. 2003; 146: 9-18